Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India

Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.

India Regulation

Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts

Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.

India Policy & Regulation

Chiesi Files India Legal Action Against Cipla Over Respiratory Therapy Patent

The Italian firm has initiated legal proceedings in India against Cipla, alleging infringement of a patent for an inhalation therapy.
Commercial Strategy

Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry

Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.

Metabolic Disorders Strategy

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Leadership Strategy

Newbie Remogliflozin Gives Competition A Run For Their Money

Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.

Commercial Strategy
See All
UsernamePublicRestriction

Register